Pascal Biosciences has entered into a term sheet with SōRSE Technology to develop Pascal’s cannabinoid programs.
Pascal Biosciences (TSXV:PAS) has entered into a term sheet with SōRSE Technology to develop Pascal’s cannabinoid programs.
As quoted in the press release:
Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.
SōRSE Technology sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and over 12 months shelf stability. SōRSE Technology is science and data-driven, with 53 employees, 30 of whom specialize in R&D and Quality Assurance. SōRSE currently has multiple partnerships which provide a profitable revenue stream.